Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887739 | 0.85 | NPC1 (0.55) | MAPTKMT2ALMNATSHRMEN1 | |
| SCHEMBL8469388 | 0.77 | SCN5A (0.46) | MAPTKMT2ATSHRCA1CA2 | |
| SCHEMBL4888633 | 0.76 | CYP1A2 (0.47) | KMT2ALMNAHPGDMPO | |
| SCHEMBL5178277 | 0.75 | NPSR1 (0.43) | MAPTKMT2ATSHRSMN1; SMN2POLB | |
| SCHEMBL4885906 | 0.74 | NPC1 (0.53) | MAPTTSHRHPGDSMN1; SMN2MPO | |
| SCHEMBL4884701 | 0.72 | SMN1; SMN2 (0.41) | MAPTKMT2ALMNATSHRCA1 | |
| SCHEMBL4888764 | 0.71 | CTSS (0.43) | MAPTKMT2ATSHRPTGS2 | |
| SCHEMBL6333408 | 0.69 | TSHR (0.67) | MAPTLMNATSHRHPGDSMN1; SMN2 | |
| SCHEMBL4891052 | 0.67 | CA9 (0.51) | CA1CA2 | |
| SCHEMBL20663366 | 0.66 | SIRT2 (0.59) | MAPTKMT2ALMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | MAPT 4293/4885KMT2A 1218/4885LMNA 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.